Navigation Links
WuXi PharmaTech Schedules First-Quarter 2013 Earnings Release
Date:4/10/2013

SHANGHAI, April 10, 2013 /PRNewswire/ -- WuXi PharmaTech (Cayman) Inc. (NYSE: WX), a leading pharmaceutical, biotechnology and medical device R&D outsourcing company with operations in China and the United States, today announced that it will release financial results for the first quarter of 2013 after the New York Stock Exchange closes on Monday, May 13, 2013 (which will be Tuesday morning, May 14, 2013 Shanghai time). The earnings release will be available on the investor relations section of the Company's website at http://www.wuxiapptec.com/.

Following the earnings announcement, WuXi PharmaTech senior management will host a conference call at 8:00 am (U.S. Eastern) / 5:00 am (U.S. Pacific) / 8:00 pm (Beijing/Shanghai/Hong Kong) on Tuesday, May 14, 2013, to discuss the first-quarter 2013 financial results and recent business activities. The conference call may be accessed by calling: United States:

1-866-519-4004 China (Landline):

800-819-0121 China (Mobile):

400-620-8038Hong Kong:

800-930-346United Kingdom:

0-808-234-6646International:

+65-6723-9381 Conference ID: 35582613A telephone replay will be available two hours after the call's completion at:

United States:

1-855-452-5696 China (Landline):

800-870-0205China (Mobile):

400-120-0932Hong Kong:

800-963-117United Kingdom:

0-808-234-0072International:

+61-2-8199-0299 Conference ID:

35582613A live webcast of the conference call and replay will be available in the investor relations section of WuXi PharmaTech's website at http://www.wuxiapptec.com/.

About WuXi PharmaTech

WuXi PharmaTech is a leading pharmaceutical, biotechnology and medical device R&D outsourcing company, with operations in China and the United States. As a research-driven and customer-focused company, WuXi PharmaTech provides pharmaceutical, biotechnology and medical device companies with a broad and integrated portfolio of laboratory and manufacturing services throughout the drug and medical device R&D process. WuXi PharmaTech's services are designed to help its global partners in shortening the cycle and lowering the cost of drug and medical device R&D. The operating subsidiaries of WuXi PharmaTech are known as WuXi AppTec.

For more information, please contact:

Ronald Aldridge
Director of Investor Relations
WuXi PharmaTech (Cayman) Inc.
Tel: +1-201-585-2048
Email: Ron_Aldridge@wuxiapptec.com
Web: http://www.wuxiapptec.com


'/>"/>
SOURCE WuXi PharmaTech (Cayman) Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Breckenridge announces agreement with Aptalis Pharmatech to market Propranolol Hydrochloride Extended-Release Capsules
2. WuXi PharmaTech Receives Letter from AAALAC Commending Animal Care at Suzhou Toxicology Facility as "Exemplary"
3. WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2012 Results, Share Repurchase Program
4. WuXi PharmaTech and Open Monoclonal Technology Expand Human Antibody Development and Commercial Opportunities for Asian Regional and Global Pharmaceutical Companies
5. WuXi PharmaTech Schedules Fourth-Quarter 2012 Earnings Release
6. WuXi PharmaTech Presents the 2012 Life Science and Chemistry Awards
7. WuXi PharmaTech Announces Shareholder Resolutions Adopted at 2012 Annual General Meeting
8. WuXi PharmaTech Celebrates Dr. Joseph Vaccas Induction into American Chemical Societys Medicinal Chemistry Hall of Fame
9. WuXi PharmaTech and Open Monoclonal Technology Announce OmniRat(TM) Antibody Collaboration
10. WuXi PharmaTech to Manufacture Ibalizumab for TaiMed Biologics
11. WuXi PharmaTech Receives GLP Certificate from SFDA for Suzhou Toxicology Facility
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2017)...  RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("the Company" ... on tissue protection, repair and regeneration, today announced ... received a positive response from the U.S. FDA ... RGN-137 to treat epidermolysis bullosa ("EB"). RGN-137 is ... beta 4 ("Tß4") as the active pharmaceutical ingredient. ...
(Date:2/27/2017)...  CTI BioPharma Corp. (CTI BioPharma) (NASDAQ and MTA: CTIC) ... Ph.D., as President and Chief Executive Officer (CEO) and member ... Craig succeeds Richard Love , interim President and CEO ... Directors.  Dr. Craig has over 20 years of experience in ... Europe . "On behalf of ...
(Date:2/24/2017)... Following receiving CE Marking in Europe ... AMAR is a major milestone for the country where the device was developed ... market in Israel   ... inclusion in the National Health Basket , Israel , ... E-QURE Corp. (OTCQB: EQUR), a leader in medical devices for the treatment of advanced wound ...
Breaking Medicine Technology:
(Date:2/27/2017)... ... February 27, 2017 , ... This webinar , sponsored ... a tool to characterize particle size distributions in the field of geoscience and ... novel scientific findings. It describes methods of optimized and standardized sample collection, preparation ...
(Date:2/27/2017)... ... February 27, 2017 , ... ... alcohol treatment programs in British Columbia, Canada, at https://www.sunshinecoasthealthcentre.ca/ , is proud ... The new hire, Mackenzie Alsager, showcases the Centre's commitment to innovation in drug ...
(Date:2/26/2017)... (PRWEB) , ... February 25, 2017 , ... The February ... Jong-un, heightened awareness and concern over nerve agents and the deadly use of chemical ... human nervous system and how even small doses can be lethal. , Jay Jagannathan, ...
(Date:2/26/2017)... York, New York (PRWEB) , ... February 26, ... ... luxury baby products for wholesale distribution in North America, today announced it would ... online sites. The company, which prides itself on crafting quality and unique baby ...
(Date:2/26/2017)... , ... February 26, 2017 , ... ... after receiving cognitive rehabilitation, according to a study released today at the 1st ... cognitive rehabilitation programs are proven to be effective in improving cognitive function in ...
Breaking Medicine News(10 mins):